Paliperidone extended-release: does it have a place in antipsychotic therapy?

Paliperidone extended-release: does it have a place in antipsychotic therapy?

Maximilian Gahr1,*, Markus A K&ouml;lle1,*, Carlos Sch&ouml;nfeldt-Lecuona1, Peter Lepping2, Roland W Freudenmann11Department of Psychiatry and Psychotherapy, University of Ulm, Ulm, Germany; 2Department of Psychiatry, Glyndwr University, Wales, UK *Both authors contributed equally a...

Full description

Bibliographic Details
Main Authors:	Carlos Sch&ouml;nfeldt-Lecuona, Markus A K&ouml;lle, Maximilian Gahr, et al
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-03-01
Series:	Drug Design, Development and Therapy
Online Access:	http://www.dovepress.com/paliperidone-extended-release-does-it-have-a-place-in-antipsychotic-th-a6649

Similar Items

Role of paliperidone extended-release in treatment of schizoaffective disorder
by: Carla M Canuso, et al.
Published: (2010-09-01)

Treatment of bipolar mania with paliperidone extended-release
by: Paterakis Periklis, et al.
Published: (2010-04-01)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
by: Yang FD, et al.
Published: (2017-04-01)

A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice
by: Bod&eacute;n R, et al.
Published: (2013-03-01)

The role of paliperidone extended release for the treatment of bipolar disorder
by: Marino J, et al.
Published: (2012-04-01)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study
by: Papanicolaou Sotiria, et al.
Published: (2009-06-01)

Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: A cost effectiveness study
by: Papanicolaou Sotiria, et al.
Published: (2008-08-01)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-02-01)

Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia
by: Edoardo Spina, et al.
Published: (2011-01-01)

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
by: Jariyavilas A, et al.
Published: (2017-01-01)

Formulation and In Vitro Evaluation of Extended Release Tablets of Paliperidone Using Natural Gums
by: bharghav bhushan rao
Published: (2018-03-01)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2008-08-01)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
by: Nakagawa R, et al.
Published: (2015-06-01)

Enhanced dermal delivery of diflucortolone valerate using lecithin/chitosan nanoparticles: in-vitro and in-vivo evaluations
by: &Ouml;zcan İ, et al.
Published: (2013-01-01)

Analysis of proarrhythmic potential of an atypical antipsychotic drug paliperidone in the halothane-anesthetized dogs
by: Koki Chiba, et al.
Published: (2017-08-01)

Antipsychotics and risk of venous thromboembolism: A population-based case-control study
by: Anna K J&ouml;nsson, et al.
Published: (2009-03-01)

National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease
by: Skogar &Ouml;, et al.
Published: (2013-07-01)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
by: Si TM, et al.
Published: (2015-01-01)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
by: Cai SL, et al.
Published: (2015-07-01)

Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
by: Malaviya AP, et al.
Published: (2012-08-01)

Randomized Controlled Trial of Paliperidone Extended Release Versus Risperidone for the Treatment of Methamphetamine-Associated Psychosis in Chinese Patients
by: Gang Wang, et al.
Published: (2020-04-01)

It is not always about gains: utilities and disutilities associated with treatment features in patients with moderate-to-severe psoriasis
by: Umar N, et al.
Published: (2012-03-01)

Psychometric properties of the Norwegian version of the General Health Questionnaire (GHQ-30) among older people living at home
by: Dale B, et al.
Published: (2012-11-01)

Narrated lived experiences of self-care and health among rural-living older persons with a strong sense of coherence
by: S&ouml;derhamn U, et al.
Published: (2011-11-01)

A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder
by: Tr&auml;nkner A, et al.
Published: (2013-01-01)

A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models.
by: Heidi N Boyda, et al.
Published: (2021-01-01)

Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia
by: Kongsakon R, et al.
Published: (2017-10-01)

Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906)
by: Scherzinger-Laude K, et al.
Published: (2013-06-01)

Effect on work ability after team evaluation of functioning regarding pain, self-rated disability, and work ability assessment
by: Jan-Rickard Norrefalk, et al.
Published: (2010-08-01)

Participation in physical and social activities among home-dwelling persons with dementia – experiences of next of kin
by: S&ouml;derhamn U, et al.
Published: (2013-06-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Anderson, M., et al.
Published: (2021)

Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews
by: Tamara Melnik, et al.

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
by: Charnsil C, et al.
Published: (2013-08-01)

Tablets of paliperidone using compression-coated technology for controlled ascending release
by: Yingying Tang, et al.
Published: (2018-03-01)

Lived experiences of self-care among older, home-dwelling individuals identified to be at risk of undernutrition
by: Tomstad ST, et al.
Published: (2012-12-01)

Ability for self-care in urban living older people in southern Norway
by: Sundsli K, et al.
Published: (2012-03-01)

Severe hepatotoxic adverse reaction in a healthy schoolgirl after treatment with flucloxacillin
by: C-J T&ouml;rnhage, et al.
Published: (2009-03-01)

Back to work: evaluation of a multidisciplinary rehabilitation program with emphasis on mental symptoms; A two-year follow up
by: Sj&ouml;str&ouml;m R, et al.
Published: (2012-06-01)

Living alone, receiving help, helplessness, and inactivity are strongly related to risk of undernutrition among older home-dwelling people
by: Tomstad ST, et al.
Published: (2012-03-01)

In vivo analysis of torsadogenic potential of an antipsychotic drug paliperidone using the acute atrioventricular block rabbit as a proarrhythmia model
by: Mihoko Hagiwara, et al.
Published: (2016-09-01)